Personal information

Emails & domains

Verified email domains

Other IDs

Scopus Author ID: 56297407200

Countries

Spain

Biography

Pharmacist and Biochemist and PhD on Biomedicine. After some years in academia, and some experience in scientific publishing I moved my career into research management. I am currently working as Project Manager at the Strategy Unit of the Institute for Bioengineering of Catalonia. The Strategy Unit is responsible for institutional projects, international alliances and partnerships and open science activities including educational activities.

Activities

Collapse all

Employment (1)

Institute for Bioengineering of Catalonia: Barcelona, ES

Employment
Source: Self-asserted source
Cristina Arimany-Nardi

Education and qualifications (1)

Universitat de Barcelona Facultat de Biologia: Barcelona, Catalunya, ES

Education
Source: Self-asserted source
Cristina Arimany-Nardi

Works (10)

ENGAGING THE SENIOR COMMUNITY IN THE ADVANCES IN BIOENGINEERING FOR HEALTH

2024-11 | Conference paper
DOI: 10.21125/iceri.2024.0641
Contributors: Cristina Arimany-Nardi; Ana Caruezo; Teresa Sanchis; PIlar Jiménez
Source: check_circle
Crossref

ENHANCING SECONDARY STEM EDUCATION: COLLABORATIVE SYNERGY BETWEEN RESEARCH AND EDUCATION CENTERS

2024-11 | Conference paper
DOI: 10.21125/iceri.2024.0352
Contributors: Luis Fernández; Rosa María Fernández-Serra; Pilar Jiménez; Santiago Marco; Eduardo Caballero; Cristina Arimany-Nardi; Teresa Sanchis; Antonio Pardo
Source: check_circle
Crossref

A Service-Learning Experience in Secondary Education to Promote STEM Learning Through Collaboration Between Research and Education Centers

European Journal of STEM Education
2024-05-28 | Journal article
DOI: 10.20897/ejsteme/14649
Part of ISSN: 2468-4368
Contributors: Luis Fernández; Rosa Maria Fernández Serra; Pilar Jiménez; Santiago Marco; Eduardo Caballero; Cristina Arimany-Nardi; Teresa Sanchis; Antonio Pardo
Source: Self-asserted source
Cristina Arimany-Nardi

Identification and Characterization of a Secondary Sodium-Binding Site and the Main Selectivity Determinants in the Human Concentrative Nucleoside Transporter 3.

Molecular pharmaceutics
2017-05 | Journal article
DOI: 10.1021/acs.molpharmaceut.7b00085
PMID: 28441873
Contributors: Arimany-Nardi C; Claudio-Montero A; Viel-Oliva A; Schmidtke P; Estarellas C; Barril X; Bidon-Chanal A; Pastor-Anglada M
Source: Self-asserted source
Cristina Arimany-Nardi via Europe PubMed Central

P-glycoprotein (ABCB1) activity decreases raltegravir disposition in primary CD4+P-gphigh cells and correlates with HIV-1 viral load.

The Journal of antimicrobial chemotherapy
2016-06 | Journal article
DOI: 10.1093/jac/dkw215
PMID: 27334660
PMC: PMC5031918
Contributors: Minuesa G; Arimany-Nardi C; Erkizia I; Cedeño S; Moltó J; Clotet B; Pastor-Anglada M; Martinez-Picado J
Source: Self-asserted source
Cristina Arimany-Nardi via Europe PubMed Central

Role of Human Organic Cation Transporter 1 (hOCT1) Polymorphisms in Lamivudine (3TC) Uptake and Drug-Drug Interactions.

Frontiers in pharmacology
2016-06 | Journal article
DOI: 10.3389/fphar.2016.00175
PMID: 27445813
PMC: PMC4919327
Contributors: Arimany-Nardi C; Minuesa G; Keller T; Erkizia I; Koepsell H; Martinez-Picado J; Pastor-Anglada M
Source: Self-asserted source
Cristina Arimany-Nardi via Europe PubMed Central

CD69 expression potentially predicts response to bendamustine and its modulation by ibrutinib or idelalisib enhances cytotoxic effect in chronic lymphocytic leukemia.

Oncotarget
2016-02 | Journal article
DOI: 10.18632/oncotarget.6685
PMID: 26701728
PMC: PMC4868702
Contributors: Montraveta A; Lee-Vergés E; Roldán J; Jiménez L; Cabezas S; Clot G; Pinyol M; Xargay-Torrent S; Rosich L; Arimany-Nardí C et al.
Source: Self-asserted source
Cristina Arimany-Nardi via Europe PubMed Central

Role of SLC22A1 polymorphic variants in drug disposition, therapeutic responses, and drug-drug interactions.

The pharmacogenomics journal
2015-11 | Journal article
DOI: 10.1038/tpj.2015.78
PMID: 26526073
Contributors: Arimany-Nardi C; Koepsell H; Pastor-Anglada M
Source: Self-asserted source
Cristina Arimany-Nardi via Europe PubMed Central

Human organic cation transporter 1 (hOCT1) as a mediator of bendamustine uptake and cytotoxicity in chronic lymphocytic leukemia (CLL) cells.

The pharmacogenomics journal
2015-01 | Journal article
DOI: 10.1038/tpj.2014.77
PMID: 25582574
Contributors: Arimany-Nardi C; Montraveta A; Lee-Vergés E; Puente XS; Koepsell H; Campo E; Colomer D; Pastor-Anglada M
Source: Self-asserted source
Cristina Arimany-Nardi via Europe PubMed Central

Nucleoside transporters and human organic cation transporter 1 determine the cellular handling of DNA-methyltransferase inhibitors.

British journal of pharmacology
2014-08 | Journal article
DOI: 10.1111/bph.12748
PMID: 24780098
PMC: PMC4128049
Contributors: Arimany-Nardi C; Errasti-Murugarren E; Minuesa G; Martinez-Picado J; Gorboulev V; Koepsell H; Pastor-Anglada M
Source: Self-asserted source
Cristina Arimany-Nardi via Europe PubMed Central
How many people are using ORCID?